Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D

Executive Summary

Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29
Advertisement

Related Content

Schering Vanceril phase-out
Serono Rebif Approval Is First Orphan Drug Challenge Based On Efficacy
Ivax acquires two Elan products
Mylan paclitaxel
Ivax Starts Shipping Generic Paclitaxel; Oral Formulation Paxoral In Phase II
Advertisement
UsernamePublicRestriction

Register

PS040741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel